LEADER 04317nam  2200697Ia 450 
001 9910143722503321
005 20170815114019.0
010   $a1-280-65334-5
010   $a9786610653348
010   $a0-470-05800-5
010   $a0-470-05801-3
035   $a(CKB)1000000000357344
035   $a(EBL)274398
035   $a(OCoLC)476018874
035   $a(SSID)ssj0000210858
035   $a(PQKBManifestationID)11198373
035   $a(PQKBTitleCode)TC0000210858
035   $a(PQKBWorkID)10291589
035   $a(PQKB)10873137
035   $a(MiAaPQ)EBC274398
035   $a(EXLCZ)991000000000357344
100   $a20050413d2006      uy             0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 00$aNew treatment strategies for dengue and other flaviviral diseases$b[electronic resource]
210   $aChichester $cJohn Wiley$d2006
215   $a1 online resource (277 p.)
225 1 $aNovartis Foundation symposium ;$v277
300   $a"Novartis Foundation symposium on new treatment strategies for dengue for dengue and other flaviviral diseases, held at the Novartis Institute for Tropical Diseases in Singapore, 26-27 September 2005"--P. v.
300   $a"Editors Gregory Bock (Organizer) and Jamie Goode"--P. v.
311   $a0-470-01643-4 
320   $aIncludes bibliographical references and index.
327   $aCover; Contents; Participants; Chair's introduction; Dengue/dengue haemorrhagic fever: history and current status; DISCUSSION; Molecular biology of flaviviruses; DISCUSSION; Development of novel antivirals against flaviviruses; DISCUSSION; Entry functions and antigenic structure of flavivirus envelope proteins; DISCUSSION; GENERAL DISCUSSION I; Multiple enzyme activities of flavivirus proteins; DISCUSSION; Towards the design of flavivirus helicase/NTPase inhibitors: crystallographic and mutagenesis studies of the dengue virus NS3 helicase catalytic domain; DISCUSSION
327   $aFinding new medicines for flaviviral targetsDISCUSSION; Structural and functional analysis of dengue virus RNA; DISCUSSION; Organization of flaviviral replicase proteins in virus-induced membranes: a role for NS1' in Japanese encephalitis virus RNA synthesis; DISCUSSION; CRM1-dependent nuclear export of dengue virus type 2 NS5; DISCUSSION; T cell responses and dengue haemorrhagic fever; DISCUSSION; The evolutionary biology of dengue virus; DISCUSSION; Developing vaccines against flavivirus diseases: past success, present hopes and future challenges; DISCUSSION
327   $aA genomics approach to understanding host response during dengue infectionDISCUSSION; Mouse and hamster models for the study of therapy against flavivirus infections; DISCUSSION; Secretion of flaviviral non-structural protein NS1: from diagnosis to pathogenesis; DISCUSSION; FINAL DISCUSSION; Contributor index; Subject Index
330   $aDengue virus is a member of the Flaviviridae family, which includes viruses associated with human diseases such as yellow fever, Japanese encephalitis and hepatitis C. Dengue fever is transmitted by mosquitoes, principally Aedes aegypti. There are four serotypes of dengue virus, of which DENV-2 has been the most prevalent in many recent epidemics. Following primary infection, lifelong immunity develops, preventing repeated assault by the same serotype. However, the non-neutralizing antibodies from a previous infection or maternally acquired antibodies are thought to form complexes with 
410  0$aNovartis Foundation symposium ;$v277.
606   $aDengue$vCongresses
606   $aFlaviviruses$vCongresses
606   $aDengue$xTreatment$vCongresses
606   $aFlaviviruses$xTreatment$vCongresses
608   $aElectronic books.
615  0$aDengue
615  0$aFlaviviruses
615  0$aDengue$xTreatment
615  0$aFlaviviruses$xTreatment
676   $a616.9185
701   $aBock$b Gregory$0322650
701   $aGoode$b Jamie$0283336
712 02$aNovartis Foundation.
712 02$aNovartis Institute for Tropical Diseases.
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910143722503321
996   $aNew treatment strategies for dengue and other flaviviral diseases$92149270
997   $aUNINA